UP!

NBS $2.32

NBS target price
2.32
0
0
Caladrius Biosciences
Type
Public
Traded as NASDAQ: CLBS
Industry Biopharmaceuticals
Founded 2006 (2006)
Headquarters New York City, New York, U.S.
Key people
David J. Mazzo (CEO)
Website caladrius.com

Caladrius Biosciences (NASDAQ: CLBS) is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.

The company was founded in 1980 and was formerly known as Corniche Group Inc, Phase III Medical Inc and NeoStem, Inc. It is headquartered in New York City, New York.

In 2012 they started a phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow derived cell therapy enriched for CD34+ cells, for Acute Myocardial Infarction. Initial results included a statistically significant mortality benefit. After the interim results reported in Nov 2014 the company clarified the changes to the study.

The cancer therapies (Melapuldencel-T and ovapuldencel-T) below are an autologous dendritic cell-based immunotherapy using the patients own dendritic cells and samples of their tumour to make dendritic cells aimed at the patients tumour antigens. This should activate T cells to attack the tumour.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2014-11-14 Resumed Maxim Group Buy $15
2014-09-18 Reiterated WBB Securities Strong Buy $27
2014-01-02 Reiterated Aegis Capital Buy $21 to $23
2013-09-12 Initiated MLV & Co Buy $16
2013-06-24 Initiated Aegis Capital Buy $2.50
2012-07-09 Upgrade WBB Securities Buy to Strong Buy $2
2012-01-19 Upgrade WBB Securities Speculative Buy to Buy $1.85 to $2
2011-09-16 Initiated JMP Securities Mkt Outperform $3
2011-08-16 Upgrade WBB Securities Hold to Speculative Buy
2010-12-03 Initiated Morgan Joseph Buy $3.50
2010-06-29 Upgrade WBB Securities Sell to Hold $1.85
2010-06-03 Initiated WBB Securities Sell $2
2010-05-27 Initiated Maxim Group Buy $5
2010-03-12 Initiated Roth Capital Buy $2.50
2014-11-14 Resumed Maxim Group Buy $15
2014-09-18 Reiterated WBB Securities Strong Buy $27
2014-01-02 Reiterated Aegis Capital Buy $21 to $23
2013-09-12 Initiated MLV & Co Buy $16
2013-06-24 Initiated Aegis Capital Buy $2.50

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In NBS 0 funds of 2213 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
RimAsia Capital Partners Manager, Ltd. 6.31%  (2222988) NBS /
RimAsia Capital Partners, L.P. 6.27%  (2210988) NBS /
Pecora Andrew L Chief Medical Officer 1.12%  (393784) CGIX / NBS / TLOG /
Smith Robin L Chairman of the Board and CEO 0.99%  (347285) NBS / RMTI / SGNL /
VATERS ROBERT S President & CFO 0.65%  (228750) NBS /
Wei Eric 0.49%  (172223) NBS /
Mazzo David J Chief Executive Officer 0.27%  (96706) AVNR / NBS / PSDV / RGDO /
LOSORDO DOUGLAS W Chief Medical Officer 0.25%  (88892) NBS /
GREENACRE MARTYN D 0.25%  (88531) CRIS / NBS /
VACZY CATHERINE M VP and General Counsel 0.20%  (71234) NBS /
MYERS STEVEN S 0.10%  (36159) NBS /
Preti Robert A See Remarks 0.10%  (33786) NBS /
Talamo Joseph See Remarks 0.09%  (30120) NBS /
Potter Stephen W 0.04%  (14016) AGTC / NBS / OSIR /
Dickey Robert IV Chief Financial Officer 0.03%  (12066) HEB / NBS /
BERNSTEIN DREW 0.03%  (10000) NBS /
KLOSK STEVEN M 0.03%  (9065) CBM / NBS /
BERMAN RICHARD J 0.02%  (7177) ADXS / APRI / NBS /
TRABER PETER G 0.02%  (6865) GALT / NBS /
BROWN GREGORY B 0.02%  (6715) CBM / NBS /